Fulcrum Therapeutics (FULC) Restructuring Costs (2022 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Restructuring Costs of $4.3 million for Q2 2026, up 109.31% quarter-over-quarter from $2.1 million in Q3 2024.
Powered by 
Analysis
Fulcrum Therapeutics (FULC) Restructuring Costs (2022 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Restructuring Costs for 3 consecutive years, with $4.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Restructuring Costs changed N/A year-over-year to $4.3 million; the TTM figure through Jun 2026 stood at $4.3 million (up 109.31% YoY), while the FY2024 annual figure was $2.1 million, changed N/A from the prior year.
- Restructuring Costs advanced to $4.3 million in Q2 2026 per FULC's latest filing, from $2.1 million in the prior quarter.
- Across five years, Restructuring Costs topped out at $4.3 million in Q2 2026 and bottomed at -$38000.0 in Q4 2022.
- Historically, Restructuring Costs has averaged $1.7 million across 3 years, with a median of $1.3 million in 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Fulcrum Therapeutics | 293.24 Mn | 293.24 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.32 Mn |
| Sep 30, 2024 | 2.06 Mn |
| Dec 31, 2022 | -38,000.00 |
| Sep 30, 2022 | 465,000.00 |